1. Home
  2. AVTX

AVTX

Avalo Therapeutics Inc.

Logo Avalo Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-24-2024 3:49pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Founded: 2011 Country:
N/A
Employees: N/A City: ROCKVILLE
Market Cap: 12.4M IPO Year: 2015
Target Price: $107.50 AVG Volume (30 days): 677.1K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -114.00 EPS Growth: N/A
52 Week Low/High: $3.95 - $1130.40 Next Earning Date: 01-01-0001
Revenue: $1,924,000 Revenue Growth: -89.34%
Revenue Growth (this year): -36.38% Revenue Growth (next year): -16.67%

Share on Social Networks: